RARE Ultragenyx Pharmaceutical Inc

$RARE patience its going to go higher $PDSB patience its going to go higher Theyneverlisten patience we will print more

$RARE 6 approved drugs, 2026 revenue guidance of $730–760M that excludes the new launches, two newly commercialized gene therapies, and a major cost reduction plan targeting profitability in 2027 , meaning revenue growth and margin expansion could happen at the same time, a rare combination for a company of this size.

When $RARE takes off I think I’m going to buy a 1969 Trans Am & start doing cocaine again.

$RARE Ultragenyx, a rare-disease drugmaker, will keep about $168M, not $210M, from selling its FDA priority review voucher: its 8-K says 20% of the gross goes to the NIH under a 2018 license. That is non-dilutive cash worth about 1.7 quarters of operating burn ($97M in Q2), on top of $436M held at June 30. The company says it supports its path to profitability in 2027. Against that: it is a one-time sale, not recurring revenue. Closing waits on an antitrust review.

$RARE $SMMT Quiet ones that would not surprise me get taken out. Theyneverlisten I give you these when nobody is watching

$RARE Is it possible that RARE share price closes green today? I've seen it happen many times. The chart does not lie we're moving up!

$RARE - At around $15, RARE offers an attractive long-term risk/reward because the market has already heavily discounted the GTX-102 setback, while the company still has a growing commercial business led by Crysvita. The recent approvals of FAYUVI and GENGLYCOS, combined with a pipeline including DTX301 and UX701, provide multiple potential growth drivers over the next several years. If Ultragenyx executes well and reaches profitability as planned, the current valuation could prove significantly undervalued. Disclouse - I am an longterm Investor with 10K share with an average price of $20.56

$RARE Buying opportunity under S20. We deserve better. They stripped us naked and spit on us. Don't get fooled with selling at $20 or less stay with it 2027 it's going to be huge. RARE will come back much stronger.

$RARE In my opinion, $RARE is arguably one of the safest biotech stocks in the market, backed by an enormous competitive moat. The company has 6 approved therapies, including two that give it a virtually exclusive position in their respective markets. Patients and families have been waiting for these treatments for years. They organize conferences, advocate tirelessly, and celebrate these life-changing FDA approvals.

$RARE $RARE looks dramatically mispriced. Six FDA-approved therapies, $214M in Q2 revenue, two new high-margin gene therapy launches, and a clear path to profitability in 2027 — yet the market cap is only ~$1.4B. Compare that with mature rare-disease peers valued at many billions. Six approved therapies. Growing revenue. New launches. Profitability ahead. At this valuation, the disconnect is hard to ignore. $45 may be much closer than the market thinks.

$RARE Today's - Resolved patent litigation with Navinta, permitting a non-exclusive, royalty-free generic DOJOLVI entry on January 1, 2033.

$RARE tutes have most of these shares locked up. They will send this back above $60 where it belongs, its a crazy spot. Being slept on, markets have not seen or digested the news yet either 👀

$RARE This. At Ultragenyx, we have developed one of the largest advanced clinical gene therapy portfolios in the industry.

$RARE hope there is a plan on way for tuesday.it better be good one or we will be stuck at this price for a long time.good luck to all.

$RARE Shorties, let me know if you need a grade school lesson on what "non-dilutive financing" means

​ $RARE - Nice!!! Ultragenyx sold PRV at good $210 M price. (They will share some with NIH as part of license agreement for Genglycos) And now they have 2nd PVR still available to sale (from Fayuvi approval for Sanfilipo syndrome gene therapy) So that will eventually bring in another $200+ M (probably more that 210)+ With the Rev ce

$RARE lost 13$ in sp because of a failed teial but 2 approvals, 370m n cash and the agreement today only adds 1$. 😂😂 crazy crazy

$RARE - This is a highly undervalued stock. It’s matter of time that it it will recover to $40 plus where it belongs or it will be acquired around that price. This is a long term investment (1-2 year) and not for someone who hopes to see a price increase in next 1-3 months

$RARE Nice new weekly option chain. Final postive needed to boost confidence considerably. Going in BIG next dip. Already have 2500 shs $14.82 avg.

$RARE I’m out..don’t want to get chances with this one as all r on the semi or tech bands. Thanks for green today!